A case report describes a patient with multiple sclerosis who had a brain tumor called a meningioma. The patient was taking a medication called natalizumab. Doctors performed gamma knife radiosurgery to treat the tumor. However, about 7 to 8 months after the surgery, the patient experienced a clinical relapse and showed multiple new lesions on an MRI.
Researchers believe the surgery may have increased the permeability of the blood-brain barrier. This could have allowed immune cells to enter the central nervous system, potentially canceling out the protective effects of the natalizumab medication. Other possibilities, such as infection or tissue death from radiation, were considered less likely.
When the patient switched to a different medication called ofatumumab, their condition became stable. Because this report only follows one patient, the findings are not enough to establish a general rule for all patients. It highlights a specific concern for doctors to monitor when combining certain surgeries with specific MS medications.
Common questions
Can gamma knife surgery cause a relapse for patients on natalizumab?
In this specific case, a patient on natalizumab experienced a clinical relapse and new lesions on an MRI 7 to 8 months after undergoing gamma knife radiosurgery. The report suggests the surgery might have increased blood-brain barrier permeability, potentially allowing immune cells to enter the central nervous system and causing a relapse.
What happened when the patient switched medications?
After the patient switched from natalizumab to a different medication called ofatumumab, the report showed that the patient achieved both clinical and radiological stability. This suggests the patient's condition stabilized after the change in treatment.
Is this a common occurrence for all patients with multiple sclerosis?
Because this is a case report involving only one patient, the findings cannot be used to determine if this happens to everyone. The study notes that the link between the surgery and the medication failure is not established as a general rule for all patients.
